Precigen PGEN
Precigen, Inc. · Nasdaq · Pharmaceutical Preparations
$5.14-25.94%close on Nov. 2, 2026 · volume 20.5M · Yahoo Finance
Price, last 50 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Aug. 26, 2026 | Jeffrey B. Kindler director | Sold | 185,000 | $7.44 | $1.38 million |
| Aug. 25, 2026 | Rutul R. Shah Chief Operating Officer | Sold 10b5-1 plan | 15,342 | $7.50 | $115,065 |
| Aug. 25, 2026 | Phil Tennant Chief Commercial Officer | Sold 10b5-1 plan | 79,166 | $7.50 | $593,745 |
| Aug. 21, 2026 | Nancy H. Agee director | Bought | 3,411 | $7.23 | $24,662 |
| Aug. 21, 2026 | Rutul R. Shah Chief Operating Officer | Sold 10b5-1 plan | 34,658 | $7.50 | $259,935 |
| Aug. 6, 2026 | Rutul R. Shah Chief Operating Officer | Sold 10b5-1 plan | 32,739 | $6.86 | $224,590 |
| Aug. 3, 2026 | Rutul R. Shah Chief Operating Officer | Sold 10b5-1 plan | 33,772 | $6.50 | $219,518 |
| July 31, 2026 | Harry Thomasian Jr. Chief Financial Officer | Sold 10b5-1 plan | 100,000 | $6.06 | $606,000 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.